Informations générales (source: ClinicalTrials.gov)
A Phase 1, Open-Label, Multicenter, Dose-Escalation and Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 in Patients With Advanced or Metastatic Prostate Cancer
Interventional
Phase 1
Genentech, Inc. (Voir sur ClinicalTrials)
mai 2023
juin 2027
17 juin 2026
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and
preliminary activity of RO7656594 in participants with advanced or metastatic prostate
cancer. It will also identify recommended doses and regimens for RO7656594 for subsequent
studies.
Etablissements
| Les établissements d'Île-de-France ayant mis à jour leurs données Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| CLCC INSTITUT GUSTAVE ROUSSY | Yohann LORIOT | 10/06/2026 06:30:07 | Contacter | ||
Critères
Homme
1. Eastern Cooperative Oncology Group (ECOG) performance status ≤1.
2. Metastatic prostate adenocarcinoma without small-cell carcinoma or neuroendocrine
features.
3. Prior therapy with a second-generation androgen receptor (AR)-targeted therapy
(e.g., abiraterone, enzalutamide, apalutamide, darolutamide).
4. Prior therapy with a taxane regimen or are considered ineligible for treatment with
a taxane regimen or have refused treatment with a taxane regimen, unless otherwise
specified.
5. For participants with a known pathogenic breast cancer gene 1 (BRCA1) or BRCA2
mutation: prior therapy with a poly (adenosine diphosphate (ADP)-ribose) polymerase
(PARP) inhibitor, or are considered ineligible for treatment with a PARP inhibitor,
if such therapy is approved and available.
Key Exclusion Criteria:
1. Treatment with any approved systemic anti-cancer therapy within 14 days or 5 drug
elimination half-lives (whichever is longer, not to exceed 28 days) prior to the
first study treatment.
2. Treatment with any investigational agent within 28 days prior to the first study
treatment.
3. Treatment with any previous AR protein degrader.
4. Untreated central nervous system (CNS) metastases or leptomeningeal disease.
Note: Other protocol specified inclusion/exclusion criteria may apply.